Figure 2.
Five-color immunohistochemical multiplex analysis of stage II CRCs based on pole and MSI status. (A) Comparisons of cell proportion of immune cells (CD8+, CD45RO+, CD8 +CD45RO+, CD3+, CD3 +PD-1+ and CD8+PD-L1+) between pole EDMs and pole wild type or non-EDMs (panel 1). (B) Comparisons of cell proportion of immune cells (CD4+, CD68+, PD-L1+, CD68+CD163-, CD68+CD163+, CD68+PD-L1+ and CD+FOXP3+) between pole EDMs and pole wild-type or non-EDMs (panel 2). (C) Comparisons of cell proportion of immune cells (CD8+, CD45RO+ and CD8+CD45RO+) between pole EDMs, MSI-H and MSS. (D) Representative immunohistochemical multiplex images of CD8+, CD45RO+ and CD8+CD45RO+ in POLE EDMs, MSI-H and MSS tumors. *P<0.05, **P<0.01, ***P<0.001. CRCs, colorectal cancer; EDMs, exonuclease domain mutations; MSI-H, microsatellite instability-high; MSS, microsatellite stable.